Awaiting a Legal Catalyst for Bayer's Stock

Bayer faces billions in legal costs, negative cash flow in 2024, but eyes a pivotal U.S. Supreme Court ruling in June that could reshape glyphosate litigation.

Investors in the German life sciences giant Bayer are currently fixated on a date in late April, as a pivotal U.S. Supreme Court hearing could dramatically alter the legal landscape surrounding tens of thousands of glyphosate-related lawsuits. This comes as the Leverkusen-based group grapples with a significant financial burden, anticipating approximately five billion euros in litigation expenses this year alone.

Financial Strain Amid Operational Resilience

The substantial legal provisions are projected to create a major deficit in the company’s cash position for 2024. Management forecasts a deeply negative free cash flow, expected to land between minus €1.5 and €2.5 billion. Consequently, net financial debt is likely to settle in the range of €32 to €33 billion by year-end. These figures stand in contrast to the underlying business performance, which has shown several positive operational signals. Looking further ahead, market analysts project an adjusted earnings per share between €4.30 and €4.80 for 2026.

The Supreme Court's "Preemption" Question

The focal point for the market is the case known as Durnell, scheduled for argument before the U.S. Supreme Court on April 27. The core legal principle at stake is "preemption." The justices will determine whether federal regulations for herbicide labeling override the authority of individual states to mandate stricter cancer warnings. A landmark ruling in Bayer's favor, expected by the end of June, would potentially remove the foundational legal basis for a large portion of the remaining claims.

Barclays Maintains a Bullish Stance

Despite the overhang of debt and litigation, some financial institutions retain a constructive view. Barclays reaffirmed its "Overweight" rating on Bayer stock last Friday, accompanied by a price target of €48. Analyst Charles Pitman-King bases his optimism on an anticipated solid operational result for the first quarter. He points to strength in the agricultural division, a sector broadly benefiting from rising commodity prices driven by higher energy costs and geopolitical tensions in the Middle East.

A Pivotal Spring Schedule for Shareholders

Before the Q1 results are published on May 12, shareholders will convene virtually for the Annual Stockholders' Meeting on April 24. A key agenda item is a vote on the proposed dividend of €0.11 per share. For the share price to sustainably break out from its current level near €40 and challenge the February high around €50, the market is seen as requiring a clear positive legal signal from Washington or unexpectedly robust operational data from the first quarter.